Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.2K
Overview
44.2K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Path dependence in immunisation programmes and how implementation science can guide system reform towards self-reliance in Africa.

BMJ public health·2026
Same author

A Systematic Review and Meta-Analysis on the Effectiveness of Interventions in Reducing Missed Opportunities for Vaccination Among Children Under Age Five.

Vaccines·2026
Same authorSame journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same author

Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.

Human vaccines & immunotherapeutics·2026
Same author

Addressing the silent epidemic of antimicrobial resistance in the African region: a scoping review of evidence gaps and research considerations.

BMJ public health·2026
Same author

Vaccine-Preventable Disease Control in the WHO African Region After the COVID-19 Public Health Emergency of International Concern: Implications for Recovery, Resilience, and System Transformation.

Vaccines·2026

Related Experiment Video

Updated: Jun 14, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Tracking Measles and Rubella Elimination Progress-World Health Organization African Region, 2022-2023.

Balcha G Masresha1, Charles Shey Wiysonge1, Reggis Katsande1

  • 1WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.

Vaccines
|August 29, 2024
PubMed
Summary

Measles and rubella elimination in the African Region faces challenges, with low vaccination coverage and surveillance gaps hindering progress. Targeted strategies are crucial to reach unvaccinated children and achieve elimination goals by 2030.

Keywords:
Africacoverageeliminationmeaslesrubellasurveillancevaccination

More Related Videos

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

13.4K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

16.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K
Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
07:40

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

13.4K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

16.7K

Area of Science:

  • Public Health
  • Epidemiology
  • Vaccinology

Background:

  • Measles and rubella elimination requires sustained absence of endemic transmission and robust surveillance.
  • The WHO African Region aims for elimination verification in 80% of countries by 2030.
  • Progress is monitored through vaccination coverage, supplementary immunization activities (SIAs), and surveillance performance.

Purpose of the Study:

  • To update progress on measles and rubella elimination in the WHO African Region.
  • To review vaccination coverage, SIAs, surveillance performance, and epidemiological trends.
  • To identify challenges and recommend strategies for achieving elimination goals.

Main Methods:

  • Review of WHO-UNICEF vaccination coverage estimates (MCV1, MCV2) for 2022-2023.
  • Analysis of measles supplementary immunization activities (SIAs) data.
  • Assessment of measles surveillance performance and epidemiological trends from case-based data.

Main Results:

  • MCV1 coverage was 69% and MCV2 coverage was 45% in 2022.
  • Rubella-containing vaccines introduced in 32/47 countries; no new introductions in 2023.
  • Measles incidence was 60.3 cases/million; 58% of suspected cases confirmed.
  • Only 55% of countries met surveillance performance targets.
  • No country has achieved measles or rubella elimination verification.

Conclusions:

  • Low routine vaccination coverage and surveillance gaps impede elimination efforts.
  • Targeted approaches to reach unvaccinated children are essential.
  • High-quality, timely SIAs remain critical for disease control and elimination.